The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is a major public health issue, but little is known about the economics of the disease. This contribution describes the epidemiology and the economics of AMD in four European countries: France, Germany, Italy and the United Kingdom (UK). We reviewed published information on AMD, including guidelines, official statistics, and local literature and interviewed AMD experts. All available health-related quality of life studies (HRQoL) on AMD were also reviewed. Data collection focused on epidemiology, medical management and resource use (both medical and non-medical items). Prevalence of AMD among persons older than 65 years is 8% and increases with age. There are two forms of the disease: atrophic (80-85% of AMD cases) and exudative, which is characterised by choroidal neovascularisation (CNV; 15-20% of AMD cases). No treatment for the atrophic form is available. Laser photocoagulation is the mainstay of treatment for CNV, although less than 30% of persons with CNV can benefit from it. Photodynamic therapy (PDT), a new treatment for CNV, reduces the risk of vision loss in forms with predominantly visible lesions. Several other new procedures are also under development. Rehabilitation and low-vision aids are useful palliative interventions when there is a residual visual acuity. The yearly budget impact of AMD was found to be between 51.3 and 101.1 million euros in the four countries studied. Information on social services and resource use was scant and little is reported on the impact of AMD on HRQoL. Economic studies of AMD should be conducted in order to assist public health decision making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the study that did not distinguish between dry AMD and nAMD patients [49], the mean annual ophthalmological care costs ranged from $20,079 to $24,606 per patient in four different countries (France, Germany, Italy and the UK).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [49]
In the citing paper
“While direct medical costs were estimated at $9.87 million for a sample of 1,164 patients in the Spanish cost analysis [48], the cross-county study (France, Germany, Italy and the UK), prevalence rates, estimated that costs ranged from $96.56 million to $190.29 million [49], using published prevalence rates.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [49]
In the citing paper
“Furthermore, costs of laser therapy, related to nAMD treatment specifically, were included in this study and represented a major cost driver (Supplementary Table 5).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [49]
In the citing paper
“Of note, eight studies [47–53, 59] did not distinguish between costs of different conditions, further hindering the interpretation.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [49]
In the citing paper
“On the other hand, a significant number of conditions, including nAMD, DR, DMO and macular oedema secondary to RVO and mCNV, are conditions for which anti-VEGF based treatments are indicated, but only a minority of this study’s results included costs of anti-VEGF injections (n = 9 [34–36, 48–50, 54–56]).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [49]
Citations
Cites
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Klein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
KAHN, H. A., LEIBOWITZ, H. M., GANLEY, J. P., KINI, M. M., COLTON, T., NICKERSON, R. S., & DAWBER, T. R. (1977) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112428 · Cited by 752
The Psychosocial Impact of Macular Degeneration
Williams, R. A. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.4.514 · Cited by 423
Quality of life of low-vision patients and the impact of low-vision services
Scott, I. U., Smiddy, W. E., Schiffman, J., Feuer, W. J., & Pappas, C. J. (1999) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(99)00108-7 · Cited by 317
Common causes of blindness and visual handicap in the west of Scotland.
Ghafour, I. M., Allan, D., & Foulds, W. S. (1983) · British Journal of Ophthalmology · doi:10.1136/bjo.67.4.209 · Cited by 306
Cataracts and Macular Degeneration in Older Americans
Klein, B. E., & Klein, R. (1982) · Archives of Ophthalmology · doi:10.1001/archopht.1982.01030030573002 · Cited by 276
Utility Values and Age-related Macular Degeneration
Brown, G. C. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.1.47 · Cited by 263
Influence of age-related maculopathy on visual functioning and health-related quality of life
Mangione, C. M., Gutierrez, P. R., Lowe, G., Orav, E. J., & Seddon, J. M. (1999) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(99)00169-5 · Cited by 255
Cited by
Age-related macular degeneration and low-vision rehabilitation: a systematic review
Hooper, P., Jutai, J. W., Strong, G., & Russell-Minda, E. (2008) · Canadian Journal of Ophthalmology · doi:10.3129/i08-001 · Cited by 491
Macrophages inhibit neovascularization in a murine model of age-related macular degeneration
Apte, R. S., Richter, J., Herndon, J., & Ferguson, T. A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030310 · Cited by 249
“dependent renal failure [35,36].”
Oxidative stress, innate immunity, and age-related macular degeneration
X. Shaw, P., 1 Department of Ophthalmology and Shiley Eye Institute, U. O. C. S. D., Stiles, T., Douglas, C., Ho, D., Fan, W., Du, H., & Xiao, X. (2016) · AIMS Molecular Science · doi:10.3934/molsci.2016.2.196 · Cited by 165
“This perspective has been supported anecdotally by several studies pinpointing smoking is the top environmental risk for developing AMD in all age and ethnic groups [74,84-89], as well as in other ocular diseases [90].”
BackgroundGlobal Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review
Schultz, N. M., Bhardwaj, S., Barclay, C., Gaspar, L., & Schwartz, J. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.08.011 · Cited by 185
Ennis, S., Jomary, C., Mullins, R., Cree, A., Chen, X., MacLeod, A., Jones, S., Collins, A., Stone, E., & Lotery, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61348-3 · Cited by 171
Metadata
- Authors
- Bonastre, J., Le Pen, C., Anderson, P., Ganz, A., Berto, P., & Berdeaux, G.
- Affiliations
- Alcon (France) (FR)
- Venue
- The European Journal of Health Economics
- Published
- 2002-06
- Volume
- 3
- Issue
- 2
- Pages
- 94-102
- ISSN
- 1439-3972 (ISSN-L)
- 1618-7598
- 1618-7601
- OpenAlex
- W2019119611
- Cited by
- 57
- References
- 38
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- The European Journal of Health Economics (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- age-related macular degeneration, prevalence, choroidal neovascularization, atrophic macular degeneration, budget impact, health-related quality of life, resource utilization (health care), laser photocoagulation, photodynamic therapy, low vision aids, rehabilitation, vision loss, public health decision-making
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. https://app.cochat.ai/papers/10.1007/s10198-002-0104-y
- The paper
- Bonastre, J., Le Pen, C., Anderson, P., Ganz, A., Berto, P., & Berdeaux, G. (2002). The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. The European Journal of Health Economics. https://doi.org/10.1007/s10198-002-0104-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.